Sponsor & Developer Portfolio
University Ghent
Clinical development pipeline, platform architecture, and registered trial tracking for University Ghent vaccine candidates.
1
Candidates
1
Target Diseases
1
Linked Studies
Development Phase Distribution
Phase 3 Clinical Trial: 1
Platform Technologies
Biological (unspecified platform): 1
Target Pathogens & Indications
Meningococcal disease
Vaccine Pipeline Candidates (1)
Detailed candidate profiles, clinical phases, target indications, and anticipated milestones.
Phase 3 Clinical Trial
ctgov-serogroup-b-meningococal-vaccine-university-ghent
Serogroup B meningococal vaccine
Target: Meningococcal disease
Platform: Biological (unspecified platform)
Key Milestone: Primary completion (most advanced trial): 2026-07-31 (registry estimate)
Explore Other Vaccine Developers & Sponsors
Compare pipeline volume, phase progression, and modalities across global biopharmaceutical manufacturers.